•  
  •  
 

Keywords

PEComa, everolimus, TSC2

Abstract

We report a case of a 63-year-old male with metastatic hepatic PEComa harboring TSC2 and NF2 mutations who achieved a durable partial response to everolimus with only mild adverse effects. This case highlights the value of genomic profiling and the efficacy of mTOR inhibitors in hepatic PEComa management.

References

1. Krawczyk M, Ziarkiewicz-Wróblewska B, Wróblewski T, et al. PEComa—a rare liver tumor. J Clin Med. 2021;10(8):1756.

2. Sobiborowicz A, ´Switaj T, Teterycz P, et al. Feasibility and long-term efficacy of PEComa treatment—20 years of experience. J Clin Med. 2021;10(10):2200.

3. Czarnecka AM, Skoczylas J, Bartnik E, ´Switaj T, Rutkowski P. Management strategies for adults with locally advanced, unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa): Challenges and solutions. Cancer Manag Res. 2023;15:615–623.

4. Rugo HS, Seneviratne L, Beck JT, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): A single-arm, phase 2 trial. Lancet Oncol. 2017;18(5):654–662.

5. Xu D, Yin S, Shu Y. NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity. npj Precis Oncol. 2024;8(1):133.

6. Sanfilippo R, Jones RL, Blay J-Y, et al. Role of chemotherapy, VEGFR inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors (PEComas). Clin Cancer Res. 2019;25(17):5295–5300.

7. Suo X, Dong R, Zhang L, Zhang X, Li X, Xiao M. TSC2-mutated perivascular epithelioid cell tumor with partial response to mTOR inhibition: A case report and literature review. Discov Oncol. 2025;16(1):1447. doi:10.1007/s12672-025-03270-z

8. Robles NR, Peces R, Gómez-Ferrer Á, et al. Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial. Orphanet J Rare Dis. 2016;11:1–9.

9. Adib E, Klonowska K, Giannikou K, et al. Phase II clinical trial of everolimus in a pan-cancer cohort of patients with mTOR pathway alterations. Clin Cancer Res. 2021;27(14): 3845–3853.

10. Meredith L, Chao T, Nevler A, et al. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: A case report. Diagn Pathol. 2023;18(1):45. doi:10.1186/s13000-023- 01323-x

Download

Share

COinS